{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:59:52Z","timestamp":1767167992663,"version":"build-2238731810"},"reference-count":17,"publisher":"Wiley","license":[{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prostate Cancer"],"published-print":{"date-parts":[[2019,2,11]]},"abstract":"<jats:p>\n                    <jats:italic>Background<\/jats:italic>\n                    . New therapies for castration-resistant prostate cancer (CRPC) may be associated with increased risk of second primary malignancies (SPM). We therefore estimated the population-based incidence of SPM among patients with CRPC in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. We also estimated the proportion of men with CRPC with bone metastases and overall survival.\n                    <jats:italic>Methods<\/jats:italic>\n                    . We conducted a retrospective cohort study of United States (US) men aged \u2265 65 years with CRPC. Cohort entry was from January 1, 2000, to December 31, 2011, with follow-up through December 31, 2013. Castration resistance was defined by treatment with second-line systemic therapy (after surgical or medical castration). SPM were diagnoses of primary cancers (other than prostate) in SEER or Medicare data.\n                    <jats:italic>Results<\/jats:italic>\n                    . Altogether 2,234 patients met eligibility criteria. Most (1,887; 84.5%) had evidence of bone metastases in Medicare claims. SPM occurred in 172 patients (incidence rate 5.9 per 100 person-years; 95% confidence interval [CI], 5.0-6.8; standardized incidence ratio = 3.1, 95% CI, 2.8-3.6, based on SEER incidence rate of all malignancies except prostate cancer among men aged \u2265 65 years). The most common SPM were lung\/bronchus (n = 29, 16.9%), urinary bladder (n = 22, 12.8%), and colon\/rectum (n = 21, 12.2%). Median survival was 1.2 years (95% CI, 1.1-1.3); 5-year survival was 9% (95% CI, 7-11%).\n                    <jats:italic>Conclusions<\/jats:italic>\n                    . This study provides the first estimate of SPM risk in older men with CRPC in the US. The incidence rate is approximately threefold higher than the population-based cancer incidence among men without prostate cancer.\n                  <\/jats:p>","DOI":"10.1155\/2019\/4387415","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T18:34:07Z","timestamp":1549910047000},"page":"1-7","source":"Crossref","is-referenced-by-count":4,"title":["Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States"],"prefix":"10.1155","volume":"2019","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-5987","authenticated-orcid":true,"given":"Catherine W.","family":"Saltus","sequence":"first","affiliation":[{"name":"RTI Health Solutions, Waltham, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdravko P.","family":"Vassilev","sequence":"additional","affiliation":[{"name":"Bayer US, Whippany, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihong","family":"Zong","sequence":"additional","affiliation":[{"name":"Bayer US, Whippany, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Calingaert","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B.","family":"Andrews","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montse","family":"Soriano-Gabarr\u00f3","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9357-4227","authenticated-orcid":true,"given":"James A.","family":"Kaye","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Waltham, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1080\/09553000902883836"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30164"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq419"},{"key":"4","year":"2015"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.002"},{"key":"6","year":"2015"},{"key":"7","first-page":"S271","volume":"20","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.10.104"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju412"},{"key":"11","year":"2016"},{"key":"12","year":"2016"},{"key":"13","year":"2016"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg077"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)72132-X"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000167176.41645.c7"},{"key":"19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/pds.4079","volume":"26","year":"2017","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e13080"}],"updated-by":[{"DOI":"10.1155\/2019\/3425982","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000}}],"container-title":["Prostate Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/pc\/2019\/4387415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/pc\/2019\/4387415.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/pc\/2019\/4387415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T18:50:51Z","timestamp":1590000651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/pc\/2019\/4387415\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":17,"alternative-id":["4387415","4387415"],"URL":"https:\/\/doi.org\/10.1155\/2019\/4387415","relation":{},"ISSN":["2090-3111","2090-312X"],"issn-type":[{"value":"2090-3111","type":"print"},{"value":"2090-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,11]]}}}